Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial

Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: امیرحسین فغفوری , بهزاد برادران , علیرضا خبازی اسکویی , مهدی عبدلی شادباد , شیما رحمانی , پرستو طلوع حیات آذر , بیت الله علیپور

کلمات کلیدی: Zinc, NLRP3, Caspase 1, Behcet syndrome, Interleukin-1beta

نشریه: 55231 , 2022 , 109 , 2022

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بیت الله علیپور
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه دانشکده تغذیه
کد مقاله 78670
عنوان فارسی مقاله Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial
عنوان لاتین مقاله Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial
ناشر 10
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Background Overproduction of NLRP3 inflammasome complex is one of the causes of Behcet's disease's (BD) auto-inflammatory nature. The aim of current study was to examine the effect of zinc supplementation on NLRP3 inflammasome expression; as well as clinical manifestations of BD. Methods In this double-blind parallel placebo-controlled randomized clinical trial, 50 BD patients were randomly allocated into either zinc gluconate (30 mg/day elemental zinc) or placebo groups for 12 weeks. The mRNA expression of NLRP3 and caspase-1 in the leukocytes, serum level of zinc and IL-1β, anthropometric measures, and clinical manifestations of patients were collected at pre- and post-intervention phase. The Iranian Behçet's disease dynamic activity measure (IBDDAM) was scored to measure the treatment effect using the calculation of number needed to treat (NNT). Analysis of covariance was performed to obtain the corresponding effect sizes. Results Zinc gluconate led to a significant improvement in genital ulcer (P = 0.019). Zinc supplementation decreased NLRP3 and caspase-1 genes expression compared with placebo group (baseline-adjusted P-value = 0.046 for NLRP3 and P-value = 0.003 for caspase-1), even after adjustment for the effect of confounding factors (baseline- and confounders-adjusted P-value = 0.032 for NLRP3 and P-value = 0.004 for caspase-1). Baseline and confounders adjusted effect size demonstrated that zinc was effective in reducing the serum level of IL-1β (P = 0.046). The NNT [95 %CI] for the rate of IBDDAM improvement was 3 [1.7–8.5]. Conclusions Zinc gluconate supplementation (30 mg/day) for a 3-month period can be considered as an adjuvant therapy in alleviating inflammation and genital ulcer among BD patients.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
امیرحسین فغفوریاول
بهزاد برادراندوم
علیرضا خبازی اسکوییسوم
مهدی عبدلی شادبادچهارم
شیما رحمانیهشتم
پرستو طلوع حیات آذرنهم
بیت الله علیپوردهم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
1_faghfouri_zinc.pdf1401/02/201102797دانلود